Human MnSOD and Cancer Research

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (10:28, 12 January 2020) (edit) (undo)
 
(3 intermediate revisions not shown.)
Line 1: Line 1:
== Human Manganese Superoxide Dismutase ==
== Human Manganese Superoxide Dismutase ==
-
<StructureSection load='2ADQ' size='340' side='right' caption='Caption for this structure' scene=''>
+
<StructureSection load='2ADQ' size='340' side='right' caption='Human superoxide dismutase complex with Mn+2 ion (small purple) and K+ ion (large purple) (PDB code [[2adq]])' scene=''>
-
This is a default text for your page '''Human MnSOD and Cancer Research'''. Click above on '''edit this page''' to modify. Be careful with the &lt; and &gt; signs.
+
-
You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref name="Azadmanesh">PMID:21638687</ref> to the rescue.
+
== History ==
== History ==
Line 8: Line 6:
== Structure ==
== Structure ==
-
Human Superoxide Dismutase (MnSOD) is a 22kD homotetrameric protein that is characterized by each subunit containing an <scene name='81/814062/N-terminus_structure/1'>N-terminus helical hairpin</scene> and alpha/beta domain that contribute to the catalytic site, the enzyme has four manganese active sites <ref name="Borgstahl et al">PMID:1394426</ref>. MnSOD alpha and beta C-terminus domains contain a “...three stranded antiparallel beta-sheet and five alpha-helices” <ref name="Borgstahl et al">PMID:1394426</ref>. The N-terminus helical hairpins are composed of “...two long antiparallel alpha-helices separated by a tight turn to form a helical hairpin” <ref name="Borgstahl et al">PMID:1394426</ref>. The active sites themselves are positioned between the helical and beta-sheet areas, while also joining the two domains <ref name="Borgstahl et al">PMID:1394426</ref>. Amino acid residues from both domains and a water molecule are responsible for the ligation of Manganese <ref name="Borgstahl et al">PMID:1394426</ref>. The four active sites associate in pairs on either side of the enzyme.
+
'''Human Superoxide Dismutase''' (MnSOD) is a 22kD homotetrameric protein that is characterized by each subunit containing an <scene name='81/814062/N-terminus_structure/1'>N-terminus helical hairpin</scene> and alpha/beta domain that contribute to the catalytic site, the enzyme has four manganese active sites <ref name="Borgstahl et al">PMID:1394426</ref>. MnSOD alpha and beta C-terminus domains contain a “...three stranded antiparallel beta-sheet and five alpha-helices” <ref name="Borgstahl et al">PMID:1394426</ref>. The N-terminus helical hairpins are composed of “...two long antiparallel alpha-helices separated by a tight turn to form a helical hairpin” <ref name="Borgstahl et al">PMID:1394426</ref>. The active sites themselves are positioned between the helical and beta-sheet areas, while also joining the two domains <ref name="Borgstahl et al">PMID:1394426</ref>. Amino acid residues from both domains and a water molecule are responsible for the ligation of Manganese <ref name="Borgstahl et al">PMID:1394426</ref>. The four active sites associate in pairs on either side of the enzyme.
-
 
+
== Function ==
== Function ==
Human Manganese Superoxide Dismutase functions to rid the cell of reactive oxygen species. Reactive oxygen species (ROS) are free radical oxygen species/molecules that are derived from molecular oxygen <ref name="Turrens">PMID:14561818</ref>. ROS will oxidize various biomolecules within the cell, whether that be fatty acids or DNA. ROS are naturally created as a byproduct of oxidative phosphorylation. In complex IV of the electron transport chain, electrons are transferred through to reduce oxygen gas to water. However, when electrons are brought into contact with oxygen via other parts of the chain, then the potential for oxygen gas to become an oxygen radical anion species <ref name="Turrens">PMID:14561818</ref>. There are a variety of defenses. One of these is MnSOD. MnSOD is present in the mitochondrial matrix, which allows it to bind and convert ROS in its active sites to produce hydrogen peroxide and oxygen gas. MnSOD has a Kcat of 40,000 1/s and a Kcat/Km of 10^9, making it one of the fastest/most efficient enzymes <ref name="Azadmanesh">PMID:29385710</ref>. The levels of MnSOD increase as certain factors like high levels of oxygen and radiation that are present through the activation of the transcription factor NF kappa B <ref name="Turrens">PMID:14561818</ref>. Human Manganese Superoxide dismutase is a current protein of interest due to its role in the protection of the mitochondrial DNA from ROS that will react and cause destruction of the nucleic acids <ref name="Borgstahl et al">PMID:1394426</ref>.
Human Manganese Superoxide Dismutase functions to rid the cell of reactive oxygen species. Reactive oxygen species (ROS) are free radical oxygen species/molecules that are derived from molecular oxygen <ref name="Turrens">PMID:14561818</ref>. ROS will oxidize various biomolecules within the cell, whether that be fatty acids or DNA. ROS are naturally created as a byproduct of oxidative phosphorylation. In complex IV of the electron transport chain, electrons are transferred through to reduce oxygen gas to water. However, when electrons are brought into contact with oxygen via other parts of the chain, then the potential for oxygen gas to become an oxygen radical anion species <ref name="Turrens">PMID:14561818</ref>. There are a variety of defenses. One of these is MnSOD. MnSOD is present in the mitochondrial matrix, which allows it to bind and convert ROS in its active sites to produce hydrogen peroxide and oxygen gas. MnSOD has a Kcat of 40,000 1/s and a Kcat/Km of 10^9, making it one of the fastest/most efficient enzymes <ref name="Azadmanesh">PMID:29385710</ref>. The levels of MnSOD increase as certain factors like high levels of oxygen and radiation that are present through the activation of the transcription factor NF kappa B <ref name="Turrens">PMID:14561818</ref>. Human Manganese Superoxide dismutase is a current protein of interest due to its role in the protection of the mitochondrial DNA from ROS that will react and cause destruction of the nucleic acids <ref name="Borgstahl et al">PMID:1394426</ref>.
 +
 +
See also [[Superoxide Dismutase]].
== Diseases/Research ==
== Diseases/Research ==
Line 18: Line 17:
SODs, in general, have also been used in response to the side effects of radiation therapy. Radiation and chemotherapy greatly increase the ROS load in both malignant and normal tissue. Although its greater in cancer cells there is still considerably toxicity in regular human tissue <ref name="Utilizing">PMID:30573187</ref>. One of the drugs being used is GC4419 which is a class of Mn (II) SOD, it is specific for the removal of superoxide and no other ROS <ref name="Utilizing">PMID:30573187</ref>. The reason this medication is thought to be protective of normal tissue is that in the differences in oxidative metabolism between the two types of cells <ref name="Utilizing">PMID:30573187</ref>. This toxicity has been found to be decreased by Superoxide dismutase which leads to improved patient recovery by aiding in the removal of ROS after treatment. Nevertheless, SODs have been shown in this type of therapy to aid in the treatment of other side effects like mucositis which are a result of the chemoradiation therapy <ref name="Utilizing">PMID:30573187</ref>. The shows the use of MnSOD in therapeutic strategies can lead to positive results for the patient. Using MnSOD to treat certain patients has shown to be quite effective with very promising results, however, the enzyme itself has a very short half-life of around six minutes <ref name="Azadmanesh">PMID:29385710</ref>. One of the ways they can increase the half-life is by using liposomal delivery which increases the half-life to four hours. Although it’s a large increase, the drawback is the MnSOD drugs must be administered regularly and often <ref name="Azadmanesh">PMID:29385710</ref>
SODs, in general, have also been used in response to the side effects of radiation therapy. Radiation and chemotherapy greatly increase the ROS load in both malignant and normal tissue. Although its greater in cancer cells there is still considerably toxicity in regular human tissue <ref name="Utilizing">PMID:30573187</ref>. One of the drugs being used is GC4419 which is a class of Mn (II) SOD, it is specific for the removal of superoxide and no other ROS <ref name="Utilizing">PMID:30573187</ref>. The reason this medication is thought to be protective of normal tissue is that in the differences in oxidative metabolism between the two types of cells <ref name="Utilizing">PMID:30573187</ref>. This toxicity has been found to be decreased by Superoxide dismutase which leads to improved patient recovery by aiding in the removal of ROS after treatment. Nevertheless, SODs have been shown in this type of therapy to aid in the treatment of other side effects like mucositis which are a result of the chemoradiation therapy <ref name="Utilizing">PMID:30573187</ref>. The shows the use of MnSOD in therapeutic strategies can lead to positive results for the patient. Using MnSOD to treat certain patients has shown to be quite effective with very promising results, however, the enzyme itself has a very short half-life of around six minutes <ref name="Azadmanesh">PMID:29385710</ref>. One of the ways they can increase the half-life is by using liposomal delivery which increases the half-life to four hours. Although it’s a large increase, the drawback is the MnSOD drugs must be administered regularly and often <ref name="Azadmanesh">PMID:29385710</ref>
-
Another project that was done regarding MnSOD and colon cancer. The research looked at Sirtuin 3, which is the predominant mitochondrial deacetylase that balances ROS concentration by the regulation of Mitochondrial proteins like MnSOD <ref name="SIRT3">PMID:29323702</ref>. The aim of the research was to identify what effect silencing SIRT3 had on the response of antioxidants, and whether this response improved the ability of the drug “Oxaliplatin” to treat colon cancer <ref name="SIRT3">PMID:29323702</ref>. The results for the knockdown of SIRT3 showed an increased number of ROS species due to the acetylation of MnSOD, which effectively deactivated MnSOD <ref name="SIRT3">PMID:29323702</ref>. This led to more apoptosis of cells due to more ROS and the presence of Oxaliplatin, which reduced the cellular viability (<ref name="SIRT3">PMID:29323702</ref>. Additionally, in another paper, researchers found that a small molecule is involved in the activation of SIRT3, this molecule called C12 binds to SIRT3 and from there SIRT 3 would '''<scene name='81/814062/Lys68/2'>Deacetylate the lys68</scene>''' residue on MnSOD <ref name="silencer">PMID:28711502</ref>. This activation would then allow the MnSOD to function to rid the cell of ROS <ref name="silencer">PMID:28711502</ref>. This is an important piece of information because it allows us to see how MnSOD is activated and deactivated in regard to the activation and knockdown of SIRT3. From this, they were able to determine a way to modify the structure of MnSOD to use it correctly for colon cancer therapies.
+
Another project that was done regarding MnSOD and colon cancer. The research looked at Sirtuin 3, which is the predominant mitochondrial deacetylase that balances ROS concentration by the regulation of Mitochondrial proteins like MnSOD <ref name="SIRT3">PMID:29323702</ref>. The aim of the research was to identify what effect silencing SIRT3 had on the response of antioxidants, and whether this response improved the ability of the drug “Oxaliplatin” to treat colon cancer <ref name="SIRT3">PMID:29323702</ref>. The results for the knockdown of SIRT3 showed an increased number of ROS species due to the acetylation of MnSOD, which effectively deactivated MnSOD <ref name="SIRT3">PMID:29323702</ref>. This led to more apoptosis of cells due to more ROS and the presence of Oxaliplatin, which reduced the cellular viability (<ref name="SIRT3">PMID:29323702</ref>. Additionally, in another paper, researchers found that a small molecule is involved in the activation of SIRT3, this molecule called C12 binds to SIRT3 and from there SIRT 3 would '''<scene name='81/814062/Lys68/4'>deacetylate the lys68</scene>''' residue on MnSOD <ref name="silencer">PMID:28711502</ref>. This activation would then allow the MnSOD to function to rid the cell of ROS <ref name="silencer">PMID:28711502</ref>. This is an important piece of information because it allows us to see how MnSOD is activated and deactivated in regard to the activation and knockdown of SIRT3. From this, they were able to determine a way to modify the structure of MnSOD to use it correctly for colon cancer therapies.

Current revision

Human Manganese Superoxide Dismutase

Human superoxide dismutase complex with Mn+2 ion (small purple) and K+ ion (large purple) (PDB code 2adq)

Drag the structure with the mouse to rotate

References

  1. 1.0 1.1 1.2 1.3 1.4 Azadmanesh J, Borgstahl GEO. A Review of the Catalytic Mechanism of Human Manganese Superoxide Dismutase. Antioxidants (Basel). 2018 Jan 30;7(2). pii: antiox7020025. doi:, 10.3390/antiox7020025. PMID:29385710 doi:http://dx.doi.org/10.3390/antiox7020025
  2. 2.0 2.1 2.2 2.3 2.4 2.5 Borgstahl GE, Parge HE, Hickey MJ, Beyer WF Jr, Hallewell RA, Tainer JA. The structure of human mitochondrial manganese superoxide dismutase reveals a novel tetrameric interface of two 4-helix bundles. Cell. 1992 Oct 2;71(1):107-18. PMID:1394426
  3. 3.0 3.1 3.2 Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol. 2003 Oct 15;552(Pt 2):335-44. doi: 10.1113/jphysiol.2003.049478. PMID:14561818 doi:http://dx.doi.org/10.1113/jphysiol.2003.049478
  4. 4.0 4.1 4.2 4.3 4.4 4.5 Dhar SK, Batinic-Haberle I, St Clair DK. UVB-induced inactivation of manganese-containing superoxide dismutase promotes mitophagy via ROS-mediated mTORC2 pathway activation. J Biol Chem. 2019 Mar 11. pii: RA118.006595. doi: 10.1074/jbc.RA118.006595. PMID:30858178 doi:http://dx.doi.org/10.1074/jbc.RA118.006595
  5. 5.0 5.1 Church SL, Grant JW, Ridnour LA, Oberley LW, Swanson PE, Meltzer PS, Trent JM. Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):3113-7. PMID:8464931
  6. 6.0 6.1 6.2 6.3 Mapuskar KA, Anderson CM, Spitz DR, Batinic-Haberle I, Allen BG, E Oberley-Deegan R. Utilizing Superoxide Dismutase Mimetics to Enhance Radiation Therapy Response While Protecting Normal Tissues. Semin Radiat Oncol. 2019 Jan;29(1):72-80. doi: 10.1016/j.semradonc.2018.10.005. PMID:30573187 doi:http://dx.doi.org/10.1016/j.semradonc.2018.10.005
  7. 7.0 7.1 7.2 7.3 Torrens-Mas M, Hernandez-Lopez R, Oliver J, Roca P, Sastre-Serra J. Sirtuin 3 silencing improves oxaliplatin efficacy through acetylation of MnSOD in colon cancer. J Cell Physiol. 2018 Aug;233(8):6067-6076. doi: 10.1002/jcp.26443. Epub 2018 Mar , 6. PMID:29323702 doi:http://dx.doi.org/10.1002/jcp.26443
  8. 8.0 8.1 Lu J, Zhang H, Chen X, Zou Y, Li J, Wang L, Wu M, Zang J, Yu Y, Zhuang W, Xia Q, Wang J. A Small Molecule Activator of SIRT3 Promotes Deacetylation and Activation of Manganese Superoxide Dismutase. Free Radic Biol Med. 2017 Jul 12. pii: S0891-5849(17)30684-6. doi:, 10.1016/j.freeradbiomed.2017.07.012. PMID:28711502 doi:http://dx.doi.org/10.1016/j.freeradbiomed.2017.07.012

Proteopedia Page Contributors and Editors (what is this?)

Jared Harrison, Michal Harel

Personal tools